There is an ongoing clinical trial sponsored by GlaxoSmithKline (GSK), one of the major providers of anti-aging supplements. The primary focus of this prospective study is to test the safety, acceptability, and the effectiveness of the use of selective androgen receptor modulator (SARM) therapy in the treatment of Alzheimer’s disease (AD). The use of SARMs has been associated with beneficial clinical outcomes in certain patients with AD; however, results from prior studies have been inconsistent across all models of treatment. Currently, there are no FDA-approved indications for such compounds.
As an anti-androgenic agent, Sarms are believed to act by interacting with the androgen receptors, resulting in reduced levels of DHT. Sarms can be administered either orally or sublingually, with positive effects noted within two months of their initial commencement.
Early research focused on the symptomatic treatment of breast cancer patients, concluding that Sarms had favorable effects in the improvement of inflammatory bowel disease symptoms, as well as an effect in the alleviation of pre-menopausal symptoms in post-menopausal women. More recent studies on Sarms have concentrated on their potential benefits in the treatment of neurodegenerative diseases, psychiatric disorders, and other physical problems associated with the aging process.
Currently, there is no evidence that the use of Sarms in human medicine can provide a reliable advance towards the treatment of age-related illnesses. One of the major benefits of the use of SARMs is that they have no significant side effects when taken alone.
In the case of people with advanced liver disease and kidney disease, doctors often recommend the use of anabolic steroids in combination with anti-inflammatory agents and statin drugs. For these patients, Sarms are a preferred option over other, more risky anti-aging interventions.
Another mk 677 benefits is that they have few inherent risks beyond the ones associated with testosterone. Since Sarms affect the production of testosterone, they also increase the body’s production of androgenic hormones (including DHEA and cortisol).
This has not been demonstrated conclusively in controlled studies. However, in non-controlled studies, low birth weight was noted in some animals treated with testosterone, and low sperm count in men is a potential risk with use of Sarms. As far as the long term effect on reproductive health goes, there is still much to be learned.
The possible benefits of Sarms appear strongest in women with breast cancer. After the removal of the tumor, the effects on breast cancer survival rates were shown to be greater than with radiation alone. In addition, women who used Sarms in the process of surgery reported a decreased incidence of recurrent breast cancer compared with those who did not use Sarms. Thus, using selective androgen receptor modulators may be useful in the treatment of postmenopausal women with breast cancer.
Testosterone and DHEA are both naturally produced by the body. In males, testosterone is converted into DHEA which is then converted into testosterone and estrogena. However, production of these hormones into the body is impaired during childhood or puberty due to a decrease in the function of the Leydig Cells (which produces testosterone) or the release of immature testosterone from the testes. In females, production of androgens and DHEA are unaffected by age and puberty.